Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits
ID: 24-007309Type: Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH - CCBETHESDA, MD, 20892, USA

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

PSC

IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS (6550)

Original Source

https://sam.gov/opp/3b5ac0426f2b468bb40275e2af7363db/view
Timeline
    Description

    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits
    The Department of Health and Human Services, Department of, National Institutes of Health, is planning to procure BD Rhapsody Single-Cell Analysis Reagent Kits. These kits are used for the manufacture of human cells and tissue-based products utilized in phase I/II clinical protocols for transplantation, adoptive immunotherapy, and gene therapy conducted in the Clinical Center at the NIH. The procurement includes a standing order for multi-type sequencing kits and reagents with a short shelf life. The contractor will be responsible for shipping the sufficient reagents and kits following the scheduled delivery dates. The shelf life of the sequencing reagents should be at least 3 months, and the shelf life of library generation kits should be at least 6 months. The contractor is also required to provide technical support for all kits and reagents at no additional cost. The period of performance for this procurement is from 5/1/2024 to 8/30/2024. The delivery schedule is overnight delivery Monday through Thursday to the Center for Cellular Engineering (CCE) at NIH/CC in Bethesda, MD. The vendor will be responsible for ensuring the safe transport of cryopreserved patient cells and maintaining the temperature and other parameters during the shipment of reagents and kits. The contractor will be paid per product delivered and is required to provide hard copies of proofs of each product delivered. Interested parties can submit their capabilities to the Office of Purchasing and Contracts by May 1st, 9:00 AM EST. Please note that this is not a request for proposal.

    Point(s) of Contact
    Damien Goines
    301568456
    damien.goines@nih.gov
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits
    Currently viewing
    Solicitation
    Similar Opportunities
    cDNA-PCR Sequencing Kits for long-read sequencing.
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for the procurement of cDNA-PCR Sequencing Kits for long-read sequencing, as part of a combined synopsis/solicitation. The primary objective is to acquire Promethion Flow Cell packs and sequencing kits to support high-throughput sequencing efforts aimed at advancing research on neurodegenerative diseases, particularly Alzheimer's disease. This procurement is crucial for the Center for Alzheimer’s Disease and Related Dementias (CARD) and is expected to facilitate the identification of causative genes and potential therapeutic targets. Interested vendors must submit their quotations by 5:00 p.m. Eastern Time on December 30, 2024, referencing Solicitation Number 75N95025Q00008, and can direct inquiries to Iris Merscher at iris.merscher@nih.gov or by phone at 301-827-2547.
    Long Sequencing Kits
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) NIDA, is seeking qualified small businesses to provide Long Sequencing Kits as part of a Sources Sought notice. The primary objective of this procurement is to acquire kits that facilitate long read sequencing for analyzing biomarkers related to Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD), which are crucial for understanding disease progression and therapeutic efficacy. The kits must meet specific technical requirements, including compatibility with Nanopore PromethION 48 sequencers and the ability to generate substantial sequencing data in real-time. Interested parties must submit their capability statements to Andrea Clay at amcgee@nida.nih.gov by December 31, 2024, at 12:00 PM Eastern Time, as this notice is strictly for research and information purposes and does not obligate the government to award a contract.
    In Vitro Biological Reagents
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), intends to negotiate a sole source procurement with Becton, Dickinson and Company for various in vitro biological reagents essential for research purposes. The procurement includes specific quantities of antibodies and reagents, such as Hu CD183 BV711 and Hu IL-13 BV421, along with shipping and handling to be delivered to Gaithersburg, Maryland. This procurement is justified under the authority of 41 U.S.C. 1901 (a)(1), indicating that only one responsible source can meet the agency's requirements. Interested parties may submit a capability statement via the NIAID electronic Simplified Acquisition Submission System (eSASS) by December 30, 2024, with all submissions considered at the Government's discretion. For further inquiries, contact Leah Hinson at leah.hinson@nih.gov.
    65--Illumina Reagents and Consumables
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Heart, Lung, and Blood Institute (NHLBI), intends to award a non-competitive contract to Illumina, Inc. for the supply of "Illumina Reagents and Consumables" essential for various sequencing and genotyping systems. This procurement is driven by the unique operational needs of NIH-owned systems, as confirmed by market research indicating that only Illumina can provide the proprietary reagents necessary to maintain research integrity and support ongoing studies. The contract performance period is set from September 3, 2025, to September 2, 2030, and interested parties may submit capability statements for review by January 6, 2025; however, this is not a solicitation for proposals. For further inquiries, interested parties can contact Ethan J. Mueller at ethan.mueller@nih.gov or by phone at +1 301 496 2153.
    Assay Kits for Lumipulse instrument
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for the procurement of assay kits for the Lumipulse instrument, aimed at quantifying specific biomarkers related to Alzheimer's Disease. The acquisition includes a total of 4,410 assays for biomarkers abeta42, abeta40, and pTau 217, which will be utilized in research involving stored samples from the Baltimore Longitudinal Study of Aging (BLSA) to assess cognitive decline and neurodegeneration. This procurement is critical for advancing Alzheimer’s research and will be awarded as a firm fixed-price purchase order, with quotations due by 5:00 p.m. Eastern Time on January 8, 2025. Interested vendors should contact Iris Merscher at iris.merscher@nih.gov for further details.
    Cytiva Sefia S-2000 Cell Processing Instrument Preventative Maintenance Services
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH) intends to award a sole source contract to Global Life Sciences Solutions USA LLC for preventative maintenance services on three Cytiva Sefia S-2000 Cell Processing Instruments located at the NIH Clinical Center in Bethesda, Maryland. The contract will cover unlimited service repair and preventive maintenance for these critical instruments used in cell therapy manufacturing and research, which are essential for compliance with FDA regulations regarding the maintenance of equipment used in drug product manufacturing. Interested parties capable of providing similar services may submit a capability statement by December 29, 2024, at 12:00 pm EST to Sheri Eiri at sheri.eiri@nih.gov for consideration in the procurement process.
    NOTICE OF INTENT FOR iSEQ 100 ADVANCE, Mi SEQ, AND NEXT SEQ 2000 SILVER SUPPORT PLAN
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), intends to negotiate a sole source contract with Illumina for a Silver Support Plan covering specific laboratory equipment, including the Nextseq 2000 and MiSeq systems. This support plan includes comprehensive services such as full coverage for parts, labor, and travel, OEM parts and service, reagent replacement due to equipment failures, scheduled maintenance visits, remote technical support, and timely on-site response, all over a 12-month term billed quarterly. The procurement is critical for maintaining the operational efficiency of NIAID's laboratory capabilities, ensuring that essential equipment remains functional and supported. Interested vendors must submit their responses via the NIAID electronic Simplified Acquisition Submission System (eSASS) by December 23, 2024, at 10:00 AM EST, and should direct any inquiries to Leah Hinson at leah.hinson@nih.gov.
    J--NICHD: Service: PacBio Sequel II Service Agreement
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Child Health and Human Development (NICHD), intends to award a sole source contract to Pacific Biosciences of California for a PacBio Sequel II Service Agreement. This procurement is essential for maintaining two advanced PacBio sequencers that are critical for NICHD researchers, ensuring their reliable operation while minimizing downtime and repair costs. The contract will cover one year of service, including preventive maintenance, software updates, remote diagnostics, and the provision of necessary reagents, with a performance period from January 11, 2025, to January 10, 2026, and the possibility of three option years. Interested parties are encouraged to submit their interest and capabilities by December 27, 2024, to determine if a competitive procurement process will be initiated. For further inquiries, contact Nicole T. Freid at nicole.freid@nih.gov or +1 301 480 6914.
    Opera Phenix Plus High-Content Screening System (or equal)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified small businesses to provide an Opera Phenix Plus High-Content Screening System or an equivalent product for the Intramural Center for Alzheimer’s and Related Dementias (CARD). The procurement aims to acquire a high-content imaging system capable of analyzing cellular samples, including organoids and tissue slices, to support research on neurodegenerative diseases. This initiative is critical for advancing the understanding of Alzheimer’s disease and related conditions through the analysis of induced pluripotent stem cells (iPSCs). Interested vendors must submit their capability statements by December 27, 2024, at 5 PM Eastern Time, to Iris Merscher at iris.merscher@nih.gov, ensuring compliance with the specified requirements and guidelines.
    Global Life Sciences Solutions Preventative Maintenance Services
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a sole-source contract for preventative maintenance services for three Sepax Pro Cell Processing Systems used in cell therapy manufacturing and research. The contract will be awarded to Global Life Sciences Solutions USA LLC, the only vendor authorized to perform these services due to the proprietary nature of the equipment and the requirement for compliance with FDA regulations regarding critical equipment maintenance. The period of performance for this contract is set from January 27, 2025, to January 26, 2026, with interested parties encouraged to submit capability statements by December 28, 2024, to Sheri Eiri at sheri.eiri@nih.gov for consideration.